Premium
Biomarkers in Clinical Drug Development
Author(s) -
Gobburu JVS
Publication year - 2009
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.57
Subject(s) - drug development , complement (music) , drug , medicine , drug approval , intensive care medicine , risk analysis (engineering) , pharmacology , biology , biochemistry , complementation , gene , phenotype
The primary purpose of this Commentary is to complement the description of biomarkers given in this issue in the Pharmaceutical Research and Manufacturers of America report by Lathia et al . I offer several examples of the use of biomarkers that highlight their value in drug development and regulatory decision making. Clinical Pharmacology & Therapeutics (2009); 86 , 1, 26–27 doi: 10.1038/clpt.2009.57